---
title: "Linzess (linaclotide), all indications: Safety questions"
description: "Safety questions on Linzess (linaclotide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: What is the Linzess boxed warning about dehydration in young children? Who should not take Linzess (contraindications)? What happens if a child accidentally swallows Linzess? How should severe diarrhea on Linzess be managed? 2 further questions follow. 6 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/linzess/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Linzess (linaclotide), all indications: Safety questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)  
Indication pages: [Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)

## Warnings

<a id="linzess-boxed-warning"></a>

### What is the Linzess boxed warning about dehydration in young children?

> “WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 
> YEARS OF AGE 
> LINZESS is contraindicated in patients less than 2 years of age; in nonclinical 
> studies in neonatal mice, administration of a single, clinically relevant adult oral 
> dose of linaclotide caused deaths due to dehydration [see Contraindications (4), 
> Warnings and Precautions (5.1), Use in Specific Populations (8.4)].”

Source: [LINZESS: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=2)

> “5.1 Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age 
> LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice (human age 
> equivalent of approximately 0 to 28 days), linaclotide increased fluid secretion as a 
> consequence of age-dependent elevated GC-C agonism which was associated with increased 
> mortality within the first 24 hours due to dehydration. There was no age-dependent trend in 
> GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; 
> however, there are insufficient data available on GC-C intestinal expression in children less 
> than 2 years of age to assess the risk of developing diarrhea and its potentially serious 
> consequences in these patients [see Warnings and Precautions (5.2) and Use in Specific 
> Populations (8.4)].”

Source: [LINZESS: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=4)

<a id="linzess-contraindications"></a>

### Who should not take Linzess (contraindications)?

> “LINZESS is contraindicated in: 
> • Patients less than 2 years of age due to the risk of serious dehydration [see Warnings 
> and Precautions (5.1), Use in Specific Populations (8.4)]. 
> • Patients with known or suspected mechanical gastrointestinal obstruction.”

Source: [LINZESS: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=4)

<a id="linzess-accidental-ingestion"></a>

### What happens if a child accidentally swallows Linzess?

> “Accidental ingestion of LINZESS in children especially in patients less than 2 years of age 
> may result in severe diarrhea and dehydration. Instruct patients to take steps to store 
> LINZESS securely and out of reach of children, and to dispose of unused LINZESS [see 
> Contraindications (4), Warnings and Precautions (5.1, 5.2)].”

Source: [LINZESS: Prescribing information, page 25, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=25)

<a id="linzess-severe-diarrhea"></a>

### How should severe diarrhea on Linzess be managed?

> “In post-marketing experience, severe diarrhea associated with dizziness, syncope, 
> hypotension and electrolyte abnormalities (hypokalemia and hyponatremia) requiring 
> hospitalization or intravenous fluid administration have been reported in patients treated with 
> LINZESS.”

Source: [LINZESS: Prescribing information, page 4, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=4)

> “If severe diarrhea occurs, suspend dosing and rehydrate the patient.”

Source: [LINZESS: Prescribing information, page 5, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=5)

> “• To stop LINZESS and contact their healthcare provider if they experience unusual or 
> severe abdominal pain, and/or severe diarrhea, especially if in combination with 
> hematochezia or melena [see Warnings and Precautions (5.2)].”

Source: [LINZESS: Prescribing information, page 25, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=25)

## Side effects

<a id="linzess-allergic-reactions"></a>

### Can Linzess cause allergic reactions?

> “The following adverse reactions have been identified during post approval use of LINZESS. 
> Because these reactions are reported voluntarily from a population of uncertain size, it is not”

Source: [LINZESS: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=8)

> “always possible to reliably estimate their frequency or establish a causal relationship to drug 
> exposure. 
>
> Hypersensitivity reactions: Anaphylaxis, angioedema, rash (including hives or urticaria)”

Source: [LINZESS: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=9)

<a id="linzess-rectal-bleeding"></a>

### Can Linzess cause rectal bleeding?

> “The following adverse reactions have been identified during post approval use of LINZESS. 
> Because these reactions are reported voluntarily from a population of uncertain size, it is not”

Source: [LINZESS: Prescribing information, page 8, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=8)

> “always possible to reliably estimate their frequency or establish a causal relationship to drug 
> exposure.”

Source: [LINZESS: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=9)

> “Gastrointestinal reactions: Hematochezia, nausea, rectal hemorrhage”

Source: [LINZESS: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=9)

## Related pages
- [Medical information: Linzess (linaclotide): All indications](https://www.evicenter.com/medical-information/linzess)
- [Indication](https://www.evicenter.com/medical-information/linzess/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/linzess/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/linzess/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/linzess/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/linzess/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/linzess/access-and-coverage)
